LINC02554: A Drug Target / Disease Biomarker (G100507657)

Target Name: LINC02554

NCBI ID: G100507657

LINC02554

Other Name(s): long intergenic non-protein coding RNA 2554 | Long intergenic non-protein coding RNA 2554

LINC02554: A Drug Target / Disease Biomarker

LINC02554 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of cell adhesion and has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

LINC02554 is a small non-coding RNA molecule that is approximately 200 amino acids in length. It is expressed in a variety of tissues and cells, including the brain, pancreas, and heart, and is highly expressed in placenta, liver, and muscle. It is also shown to be expressed in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of LINC02554 is its role as a regulator of cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. LINC02554 is shown to be involved in the regulation of cell-cell adhesion, as well as cell-cell and cell-extracellular matrix adhesion. This is important because many diseases, including cancer, are caused by disruptions in cell adhesion.

In addition to its role in cell adhesion, LINC02554 is also shown to play a role in the regulation of gene expression. It has been shown to interact with a variety of transcription factors, including TGF-β1, NF-kappa-B, and SMAD. This is important because these transcription factors are responsible for regulating the expression of many genes that are involved in various cellular processes.

The potential drug target status of LINC02554 is supported by several studies. First, there is evidence that LINC02554 can be targeted by small molecules, such as inhibitors of tyrosine kinase activity. This suggests that LINC02554 may be a good candidate for drug development. Second, there is evidence that LINC02554 is involved in the regulation of cellular processes that are often disrupted in diseases, such as cancer and neurodegenerative diseases. This suggests that it may be a useful biomarker for these diseases.

Finally, there is evidence that LINC02554 may be involved in the regulation of cellular processes that are important for the development and progression of diseases. For example, LINC02554 has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels grow in response to the need for oxygen and nutrients. This suggests that LINC02554 may be a useful target for diseases that are caused by disruptions in angiogenesis, such as cancer.

In conclusion, LINC02554 is a non-coding RNA molecule that has been shown to play a role in the regulation of cell adhesion and gene expression. It is also a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of LINC02554 in these diseases and to develop effective treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 2554

The "LINC02554 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02554 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets